Literature DB >> 21193351

Ocular manifestations of multiple myeloma: three cases and a review of the literature.

Kimberly J Chin1, Sanford Kempin, Tatyana Milman, Paul T Finger.   

Abstract

BACKGROUND: Multiple myeloma is the most common plasma cell tumor; however, ocular plasmacytomas are rare and can appear in almost any structure of the eye. We present 3 cases, including 2 with unique ophthalmic ultrasound images of ocular plasmacytoma. CASE REPORTS: Three patients with ocular manifestations of multiple myeloma are described. All were noted to have known synchronous systemic disease. In this study, patients presented with epibulbar (n = 2), iridociliary (n = 1), and orbital (n = 2) plasmacytomas. Presenting signs included clinically visible tumor (n = 2), blurred vision (n = 2), diplopia (n = 2), and glaucoma (n = 1). The iridociliary plasmacytoma was defined by high-frequency 35-MHz ultrasonography that revealed 360° of anterior chamber involvement, secondary angle-closure, and extent of iridociliary invasion. In another case, low-frequency B-scan ultrasonography found multiple myeloma of the orbit. Ocular manifestations of multiple myeloma, histopathology, treatment, and prognosis are described.
CONCLUSION: Ocular manifestations of plasma cell neoplasms are rare. In multiple myeloma, plasmacytomas can present as a solitary tumor, as an initial sign of systemic disease, or as recurrence. This study presents 3 cases in which epibulbar, orbital, and iridociliary plasmacytoma with secondary glaucoma were presenting signs of uncontrolled multiple myeloma.
Copyright © 2010 American Optometric Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21193351     DOI: 10.1016/j.optm.2010.10.009

Source DB:  PubMed          Journal:  Optometry        ISSN: 1558-1527


  8 in total

1.  [Retinal manifestation in hematological diseases].

Authors:  M Rehak; N Feltgen; P Meier; P Wiedemann
Journal:  Ophthalmologe       Date:  2018-09       Impact factor: 1.059

2.  Intraocular plasmacytoma: A case of iris involvement and a review of the literature.

Authors:  Kafayat A Oyemade; Scott L Stafford; Morie A Gertz; Sanjay V Patel; Keith H Baratz; Lauren A Dalvin
Journal:  Am J Ophthalmol Case Rep       Date:  2022-04-10

3.  Asymmetric optic disc edema in a young patient with POEMS: A rare presentation of a rare disease.

Authors:  Hana Mahallati; James Kirkland Roberts; Amer Assal; Divaya Bhutani; David C Park; Golnaz Moazami
Journal:  Am J Ophthalmol Case Rep       Date:  2021-03-16

4.  Ocular Manifestations in Hematological Disorders.

Authors:  Mohamed Bouazza; Houda Youssefi; Nouama Bouanani
Journal:  Cureus       Date:  2022-08-12

5.  Multiple myeloma of the orbit.

Authors:  Mona Hassan; Zaid Alirhayim; Laila Sroujieh; Syed Hassan
Journal:  Case Rep Ophthalmol Med       Date:  2012-11-06

6.  Poststreptococcal syndrome mimicking conjunctival lymphoma.

Authors:  Iwona Rospond-Kubiak; Agata Brązert; Jarosław Kocięcki; Jan Bręborowicz
Journal:  BMC Infect Dis       Date:  2013-03-25       Impact factor: 3.090

7.  Efficacy of lenalidomide in association with cyclophosphamide and dexamethasone in multiple myeloma patient with bilateral retro-orbital localisation.

Authors:  S Felici; N Villivà; G Balsamo; A Andriani
Journal:  Ecancermedicalscience       Date:  2013-07-10

Review 8.  Hidden in the Eyes-Recurrence of Systemic Hemopathies Reportedly "In Remission": Six Cases and Review of Literature.

Authors:  Margot Denier; Sarah Tick; Romain Dubois; Remy Dulery; Andrew W Eller; Felipe Suarez; Barbara Burroni; Claude-Alain Maurage; Claire Bories; Johanna Konopacki; Michel Puech; Didier Bouscary; Alberte Cantalloube; Emmanuel Héron; Ambroise Marçais; Christophe Habas; Vincent Theillac; Chafik Keilani; Gabrielle R Bonhomme; Denise S Gallagher; Julien Boumendil; Wajed Abarah; Neila Sedira; Stéphane Bertin; Sylvain Choquet; José-Alain Sahel; Lilia Merabet; Françoise Brignole-Baudouin; Marc Putterman; Marie-Hélène Errera
Journal:  Medicina (Kaunas)       Date:  2022-03-21       Impact factor: 2.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.